301 related articles for article (PubMed ID: 31787372)
1. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
4. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.
Abdoellakhan RA; Khorsand N; Ter Avest E; Lameijer H; Faber LM; Ypma PF; Nieuwenhuizen L; Veeger NJGM; Meijer K
Ann Emerg Med; 2022 Jan; 79(1):20-30. PubMed ID: 34535300
[TBL] [Abstract][Full Text] [Related]
5. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
6. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
[TBL] [Abstract][Full Text] [Related]
8. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal.
Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM
Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496
[TBL] [Abstract][Full Text] [Related]
9. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K
Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580
[TBL] [Abstract][Full Text] [Related]
10. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
11. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
[TBL] [Abstract][Full Text] [Related]
13. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
Schwebach AA; Waybright RA; Johnson TJ
Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
[TBL] [Abstract][Full Text] [Related]
14. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
Yohe AS; Livings SE
Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
[TBL] [Abstract][Full Text] [Related]
15. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
Fuh L; Goldstein JN; Hayes BD
J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
[TBL] [Abstract][Full Text] [Related]
16. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
[TBL] [Abstract][Full Text] [Related]
17. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
Hood C; Goldstein JN; Milling TJ; Refaai MA; Bajcic P; Goldstein B; Sarode R
Blood Adv; 2023 May; 7(10):2206-2213. PubMed ID: 36574241
[TBL] [Abstract][Full Text] [Related]
18. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
19. Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal.
Bizzell AC; Mousavi MK; Yin E
Int J Hematol; 2021 Sep; 114(3):334-341. PubMed ID: 34191234
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
